Erin Duhaime, PA
Medical · Dallas, TXNPI 1801041009
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,312 of the $149,540 with a category attached, or 64.4%. Viiv Healthcare Company accounts for 71.8% of it on its own, with 37 other manufacturers making up the rest. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 875 payments — averaging $170.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$107K
- Ferring Pharmaceuticals Inc.$22K
- Merck$11K
- Gilead$3K
- Theratechnologies Inc.$928
- AbbVie$818
- plus $5K from 32 others
What the payments were for
- Consulting fees$7,5805%
- Speaking & faculty fees$96,31264%
- Travel & lodging$20,77114%
- Food & beverage$23,16015%
- Education$1,7171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 405 | $107,390 |
| Ferring Pharmaceuticals Inc. | 39 | $21,514 |
| Merck | 63 | $11,057 |
| Gilead | 73 | $2,671 |
| Theratechnologies Inc. | 25 | $928 |
| AbbVie | 40 | $818 |
| Janssen Research & Development, LLC | 8 | $620 |
| Insmed, Inc. | 25 | $614 |
| Shionogi Inc | 27 | $462 |
| Astellas Pharma US Inc | 17 | $443 |
| Paratek Pharmaceuticals, Inc. | 27 | $372 |
| Johnson & Johnson | 24 | $362 |
| EMD Serono, Inc. | 20 | $358 |
| Napo Pharmaceuticals Inc | 12 | $271 |
| Janssen Products, LP | 3 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $263 |
| La Jolla Pharmaceutical Company | 7 | $143 |
| Aimmune Therapeutics, Inc. | 5 | $117 |
| Amgen | 4 | $90 |
| Pfizer | 4 | $86 |
| Grifols USA, LLC | 3 | $66 |
| Cumberland Pharmaceuticals, Inc. | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $60 |
| Novo Nordisk | 3 | $56 |
| Octapharma USA, Inc. | 2 | $53 |
| Melinta Therapeutics, LLC | 3 | $45 |
| Mayne Pharma Commercial LLC | 2 | $44 |
| Antares Pharma, Inc. | 3 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Halozyme Inc | 1 | $22 |
| GSK | 1 | $21 |
| Tolmar, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,540 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 170 | $697,681 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 112 | $548,058 |
| DovatoDolutegravir Sodium/Lamivudine | 161 | $495,581 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 80 | $327,660 |
| PifeltroDoravirine | 150 | $277,398 |
| TivicayDolutegravir Sodium | 91 | $229,381 |
| RukobiaFostemsavir Tromethamine | 20 | $199,205 |
| PrezcobixDarunavir/Cobicistat | 80 | $197,562 |
| DescovyEmtricitabine/Tenofov Alafenam | 80 | $181,174 |
| CabenuvaCabotegravir/Rilpivirine | 27 | $174,969 |
| IsentressRaltegravir Potassium | 36 | $70,447 |
| JulucaDolutegravir/Rilpivirine | 17 | $64,918 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 14 | $58,468 |
| Etravirine | 48 | $50,824 |
| Isentress HdRaltegravir Potassium | 19 | $41,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay, Rukobia, Cabenuva | $107,390 | $1,491,712396 claims |
| GileadBiktarvy, Descovy, Stribild | $2,671 | $937,323264 claims |
| Janssen Products, LPSymtuza | $268 | $548,058112 claims |
| MerckPifeltro, Isentress, Isentress Hd | $11,057 | $389,736205 claims |
| Johnson & JohnsonPrezcobix | $362 | $197,56280 claims |
| Janssen Scientific Affairs, LLCEdurant, Prezista | $29 | $58,17334 claims |
| Napo Pharmaceuticals IncMytesi | $271 | $29,43312 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $18 | $23,48925 claims |
| Novo NordiskOzempic | $56 | $16,38519 claims |
| Antares Pharma, Inc.Xyosted | $41 | $14,83424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in Dallas
- Kimberly PoarchDallas$166K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
- Andrew GarzaDallas$43K
- Alyssa SpiegelDallas$18K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.